21.08 -0.01 (-0.06%)
After hours: 5:24PM EDT
|Bid||20.30 x 100|
|Ask||21.45 x 100|
|Day's Range||20.83 - 21.28|
|52 Week Range||18.03 - 32.50|
|PE Ratio (TTM)||42.78|
|Earnings Date||May 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.29|
In February 2018, Exelixis (EXEL) and its partner Daiichi Sankyo announced that it had submitted a regulatory application for esaxerenone therapy to the Japanese Pharmaceutical and Medical Devices Agency for the treatment of individuals with hypertension. According to the prior agreement between Exelixis and Daiichi Sankyo, Exelixis is set to receive a milestone payment of $20 million from Daiichi Sankyo. Daiichi Sankyo’s regulatory application has been supported by the results of Phase 3 trials evaluating the safety and efficacy of esaxerenone in individuals with essential hypertension compared to eplerenone.
In March 2018, the FDA accepted Exelixis’s (EXEL) supplemental New Drug Application (or sNDA) for Cabometyx as a therapy for the treatment of individuals with advanced hepatocellular carcinoma (or HCC) who have previously undergone therapy. Exelixis’s sNDA was based on the results of its Phase 3 CELESTIAL trial. In October 2017, an independent data-monitoring committee recommended that Exelixis stop its CELESTIAL efficacy trial after a review of the second planned interim analysis, wherein Cabometyx demonstrated statistically significant and clinically meaningful progress in overall survival compared to the placebo in individuals who had already been treated for advanced HCC.
In 4Q17, Exelixis’s (EXEL) Cabometyx reported revenue of $90.4 million compared to $44.7 million in 4Q16, which reflected a ~102% rise on a YoY (year-over-year) basis. The FDA’s approval of the drug’s label expansion also boosted its revenue growth in 4Q17. In 2017, Cabometyx generated revenue of $324 million compared to $93.5 million in 2016.
In 4Q17, Exelixis (EXEL) generated revenue of $115.9 million compared to $75.7 million in 4Q16, which reflected a ~55% rise on a year-over-year (or YoY) basis and a ~19% fall on a quarter-over-quarter basis. In 4Q17, Exelixis generated revenue of $95.7 million from net product sales and $24.4 million from collaborations. In 4Q17, Cabometyx primarily pushed this revenue growth.
NEW YORK, April 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Exelixis, Inc. announced today that its first quarter 2018 financial results will be released on Wednesday, May 2, 2018 after the markets close. At 5:00 p.m. EDT / 2:00 p.m.
Exelixis shares rebounded Tuesday from a 10-month low at Monday's close after regulators temporarily halted enrollment in a cancer study combining drugs from Exelixis and Roche.
NEW YORK, NY / ACCESSWIRE / April 10, 2018 / U.S. markets rallied in early trading Monday on the strength of technology stocks and the easing of trade relations between the U.S. and China. However, most ...
Exelixis, Inc. today announced that renowned biomedical research executive Maria C. Freire, Ph.D. has been elected to the company’s Board of Directors. Dr. Freire’s appointment took effect on April 5, 2018.
NEW YORK, NY / ACCESSWIRE / April 5, 2018 / After falling sharply on global trade fears in early trading Wednesday, U.S. stocks rallied to close in the green. The Dow Jones Industrial Average touched a ...
A battle brewing in liver cancer will land Exelixis on top, an analyst said Wednesday after rival Eli Lilly posted strong topline results for its drug.
Exelixis (EXEL) has witnessed a significant price decline in the past four weeks, and has seen negative earnings estimate revisions for the current quarter and year.
Stock Monitor: ChemoCentryx Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 02, 2018 / Active-Investors.com has just released a free research report on Exelixis, Inc. (NASDAQ: EXEL ). If you want ...
NEW YORK, NY / ACCESSWIRE / March 29, 2018 / U.S. markets fell for the second consecutive session Wednesday as the tech sector’s struggles continued. The Dow Jones Industrial Average declined 0.04 percent ...
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Exelixis, Inc. today announced that its partner Ipsen received validation of the application for variation to the CABOMETYX® marketing authorization from the European Medicines Agency , the European regulatory authority, for the addition of a new indication for patients with previously treated advanced hepatocellular carcinoma .
Exelixis' European partner, Ipsen, obtains positive opinion from the CHMP for the use of Cabometyx in the first-line treatment of advanced renal cell carcinoma.